Artiva Biotherapeutics, INC Form 4 insider transactions
NASDAQ
Form 4: RA Capital Management Reports Beneficial Ownership Changes in Artiva Biotherapeutics Following IPO
RA Capital Management and related entities report changes in beneficial ownership of Artiva Biotherapeutics common stock following the company's initial public offering.
NASDAQ
Form 4: Artiva Biotherapeutics: 5AM Partners VI, LLC Reports Beneficial Ownership Changes Following IPO
5AM Partners VI, LLC and related entities report changes in beneficial ownership of Artiva Biotherapeutics (ARTV) common stock following the company's initial public offering (IPO).
NASDAQ
Wellington Biomedical Innovation Master Investors reports the conversion of Series B Preferred Stock and a SAFE into Artiva Biotherapeutics common stock following the company's IPO.
NASDAQ
VenBio Global Strategic Fund III, L.P. reports conversion of preferred stock and SAFE agreements into common stock following Artiva Biotherapeutics' IPO.
NASDAQ
Form 4: GC Corp. and GC Cell Corp. Report Changes in Ownership of Artiva Biotherapeutics Following IPO
GC Corp. and GC Cell Corp. report changes in beneficial ownership of Artiva Biotherapeutics common stock following the company's initial public offering.
NASDAQ
Form 4: Artiva Biotherapeutics Insider Filing: GC Corp and GC Cell Increase Common Stock Holdings Post-IPO
Yong-Jun Huh, as a director and related to significant shareholders GC Corp and GC Cell Corporation, reports transactions related to the conversion of preferred stock and SAFE agreements into common stock following Artiva Biotherapeutics' IPO.
NASDAQ
CEO Fred Aslan reports the acquisition of restricted stock units and stock options in Artiva Biotherapeutics.